10 Best Performing Penny Stocks to Buy Now

5. Editas Medicine Inc. (NASDAQ:EDIT)

Share Price: $3.09

Year To Date Gain: 133.97%

Number of Hedge Fund Holders: 11

Editas Medicine Inc. (NASDAQ:EDIT) is one of the best performing penny stocks to buy now. On September 5, HC Wainwright reiterated a “Buy” rating on the stock and a $5 price target. The positive stance follows the nomination of EDIT-401 as the company’s lead Vivo program.

The company is developing EDIT-401 as a one-time therapy for reducing LDL cholesterol levels. The company is developing the program as an experimental, transformative in vivo gene editing medicine based on an upregulation approach.

EDIT-401 is designed to treat hyperlipidemia by directly editing the LDLR gene to increase LDLR protein expression and reduce LDL-C levels. Its nomination as a lead in vivo development candidate marks a significant milestone in Edita’s long-term vision to lead the field of in vivo programmable gene editing.

“At Editas Medicine, we believe in vivo is the future of medicine. With EDIT-401, we’re advancing our differentiated upregulation strategy to develop a next-generation medicine that can deliver lasting impact for patients,” said Gilmore O’Neill, Chief Executive Officer of Editas Medicine.

Editas Medicine Inc. (NASDAQ:EDIT) is a genome-editing company that develops transformative medicines for individuals with severe, genetically defined diseases using CRISPR-based technology. The company focuses on discovering, developing, and commercializing durable, precise, in vivo (within the body) gene-editing therapies that can correct or modify disease-causing genes.